Literature DB >> 19829315

Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment.

P C Huszthy1, H Immervoll, J Wang, D Goplen, H Miletic, G E Eide, R Bjerkvig.   

Abstract

The objective of the present study was to evaluate the cellular effects of the oncolytic HSV-1 based vector, G207, on the tumor microenvironment. We established progressively growing intracerebral xenografts in athymic nude rats generated from three different human GBM surgical specimens. The lesions were identified by MRI and subsequently injected with a concentrated vector stock. The animals were killed 10 or 30 days after G207 injection and the tumors were quantitatively evaluated for virus-induced changes in proliferation, apoptosis and vascularity. Moreover, we assessed vector spread as well as the infiltration pattern of CD68-positive inflammatory cells. In all G207-injected lesions, immunostaining identified widespread regions of viral infection and replication (plaques). Proliferation indices were significantly lower, whereas apoptotic counts were significantly elevated in plaques as compared with that in non-infected areas of the same lesions, as well as in corresponding control xenografts. Furthermore, there was a significant decline in the number of blood vessels in the plaques and the vascular area fractions were reduced. CD68-positive inflammatory cells accumulated in the plaques. The present study highlights the favorable cellular responses to G207 treatment seen from a clinical viewpoint, such as reduced tumor cell proliferation, more frequent events of tumor cell death and a strongly attenuated tumor vascular compartment. However, our results suggest that transduction of a significant volume of tumor tissue is essential, as these beneficial changes were only observed in areas of active viral replication, leaving non-transduced tumor tissues unaffected.

Entities:  

Mesh:

Year:  2009        PMID: 19829315     DOI: 10.1038/gt.2009.130

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

2.  Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

Authors:  James M Markert; James J Cody; Jacqueline N Parker; Jennifer M Coleman; Kathleen H Price; Earl R Kern; Debra C Quenelle; Alfred D Lakeman; Trenton R Schoeb; Cheryl A Palmer; Samuel C Cartner; G Yancey Gillespie; Richard J Whitley
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 3.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

Review 4.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 5.  MR imaging features of high-grade gliomas in murine models: how they compare with human disease, reflect tumor biology, and play a role in preclinical trials.

Authors:  A R Borges; P Lopez-Larrubia; J B Marques; S G Cerdan
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

6.  A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.

Authors:  Qian Zhao; Wen Zhang; Zhifeng Ning; Xiufen Zhuang; Haizhen Lu; Jing Liang; Jie Li; Yu Zhang; Ying Dong; Youhui Zhang; Shuren Zhang; Shangmei Liu; Binlei Liu
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

Review 7.  Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

Authors:  Victor A Naumenko; Aleksei A Stepanenko; Anastasiia V Lipatova; Daniil A Vishnevskiy; Vladimir P Chekhonin
Journal:  Mol Ther Oncolytics       Date:  2022-02-12       Impact factor: 7.200

8.  Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition.

Authors:  Yoshihiro Otani; Ji Young Yoo; Samantha Chao; Joseph Liu; Alena Cristina Jaime-Ramirez; Tae Jin Lee; Brian Hurwitz; Yuanqing Yan; Hongsheng Dai; Joseph C Glorioso; Michael A Caligiuri; Jianhua Yu; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2020-03-05       Impact factor: 12.531

Review 9.  The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.

Authors:  Ifeanyi Kingsley Uche; Konstantin G Kousoulas; Paul J F Rider
Journal:  Viruses       Date:  2021-06-22       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.